Please login to the form below

Not currently logged in
Email:
Password:

cancer vaccine

This page shows the latest cancer vaccine news and features for those working in and with pharma, biotech and healthcare.

Newly-listed BioNTech buys Neon to boost cell therapy assets

Newly-listed BioNTech buys Neon to boost cell therapy assets

BioNTech has agreed to pay $67m for Cambridge, Massachusetts-based Neon, which ended 2019 on a sour note by dropping its clinical-stage personalised cancer vaccine NEO-PV-01 after disappointing ... Also in the pipeline is NEO-STC-01, another RAS-targeted

Latest news

  • Merck strengthens KRAS stake with Taiho and Astex partnership Merck strengthens KRAS stake with Taiho and Astex partnership

    At MSD we continue to pursue new regimens designed to extend the benefits of highly selective therapies to more patients with cancer,” said Roger Perlmutter (pictured left), president, MSD Research Laboratories. ... Merck also has an ongoing

  • Merck CFO: we’re not only about Keytruda Merck CFO: we’re not only about Keytruda

    He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer ... vaccine Gardasil and HIV franchise – is

  • GSK eyes follow-up HPV vaccine GSK eyes follow-up HPV vaccine

    Cervarix from the US market after finding it was not competitive against rival Merck &Co’s HPV vaccine. ... Innovax has already developed a cervical cancer vaccine, Cecolin, which is HPV 16 &18 bivalent – these two HPV types are known to cause at

  • Boehringer’s head of pharma heads for the exit Boehringer’s head of pharma heads for the exit

    Carine Bruillon. Recent deals have included a 325m acquisition of AMAL Therapeutics to gain access to its cancer vaccine technology, a $226m alliance with UK-listed biotech PureTech Health to develop ... a new approach to cancer immunotherapy, a 1.1bn

  • Boehringer posts solid first half as business revamp beds in Boehringer posts solid first half as business revamp beds in

    Last month for example it signed a 325m deal to acquire AMAL Therapeutics to gain access to its cancer vaccine technology, and in April forged a $226m alliance with UK-listed ... biotech PureTech Health to develop a new approach to cancer immunotherapy.

More from news
Approximately 2 fully matching, plus 147 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?

  • Pharma deals in August 2015 Pharma deals in August 2015

    This was the fifth deal announced by AstraZeneca/Medimmune in the month under which the company gained access to INO-3112 a cancer vaccine which targets cancers caused by human papilloma ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112

  • Pharma deals in March 2015 Pharma deals in March 2015

    The companies will collaborate to develop three anti-cancer drugs, one Mab from Lilly and a Mab and an additional molecule from Innovent. ... This is what BMS has secured with Bavarian Nordic's cancer vaccine targeting PSA in phase III for treatment of

  • Pharma deals in February 2015 Pharma deals in February 2015

    This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    R&D and. commercialisation. IMA942 tumour-associated peptide cancer vaccine candidates in NSCLC and prostate cancer. ... BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Secondary effects of COVID-19 on the healthcare system and patients

    To date, most of the focus has understandably been on the immediate effects of the virus and the efforts to enforce physical distancing and develop a vaccine.

  • Understanding the "Big Picture"

    A good example of this is Globocan cancer epidemiology data, which is extremely high level but does not provide insight as to staging or treatment rates. ... A good example of this “Risk-awareness thinking” would be the impact of the cervical cancer

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics